Dados do Trabalho

Title

Efficacy and safety of ovarian stem cell transplantation in patients with primary ovarian insufficiency and poor ovarian response: a systematic review.

Objective

The aim of this study was to conduct a systematic review to assess the effectiveness and safety of mesenchymal stem cell transplantation as a therapeutic approach for patients with reduced ovarian function or poor response to infertility treatments.

Methods

A systematic review was performed, encompassing studies published within the past decade (from January 2012 to June 2022). PubMed, Cochrane Library, Scopus, and the National Library of Medicine databases were utilized as primary sources. The PRISMA Statement, 2020, was followed for the checklist of materials and methods. The risk of bias in the studies was evaluated using the Cochrane Risk of Bias (RoB) 2.0 tool, with assessments carried out independently by two reviewers. The systematic review was registered on the Prospero platform with the identifier number CRD42022354259.

Results

Fifteen studies that met the selection criteria were within the scope of this review. These studies assessed stem cell transplantation in patients with diminished ovarian function or poor ovarian response. Data were summarized and organized in two tables according to study design, degree of ovarian failure, source of stem cells, route of administration and dose applied, follow-up and other criteria.

Conclusion

Based on the analysis of studies that fulfilled the inclusion criteria, it can be inferred that there is a notable scarcity of randomized trials with substantial patient cohorts. Additionally, there was an absence of studies evaluating the safety of long-term therapy proposed by ovarian stem cell transplantation. Considering the obtained results, ovarian stem cell transplantation holds promise as a potential therapeutic approach for this group of patients, who currently lack established treatment options.

Keywords

Female infertility; Primary ovarian insufficiency; Poor responder; Cell therapy; Mesenchymal stem cells.